作者
Federico Storni, Andris Zeltins, Ina Balke, Matthew D Heath, Matthias F Kramer, Murray A Skinner, Lisha Zha, Elisa Roesti, Paul Engeroff, Lukas Muri, Diego Von Werdt, Thomas Gruber, Mark Cragg, Malgorzata Mlynarczyk, Thomas M Kündig, Monique Vogel, Martin F Bachmann
发表日期
2020/4/1
期刊
Journal of Allergy and Clinical Immunology
卷号
145
期号
4
页码范围
1240-1253. e3
出版商
Mosby
简介
Background
Peanut allergy is a severe and increasingly frequent disease with high medical, psychosocial, and economic burden for affected patients and wider society. A causal, safe, and effective therapy is not yet available.
Objective
We sought to develop an immunogenic, protective, and nonreactogenic vaccine candidate against peanut allergy based on virus-like particles (VLPs) coupled to single peanut allergens.
Methods
To generate vaccine candidates, extracts of roasted peanut (Ara R) or the single allergens Ara h 1 or Ara h 2 were coupled to immunologically optimized Cucumber Mosaic Virus–derived VLPs (CuMVtt). BALB/c mice were sensitized intraperitoneally with peanut extract absorbed to alum. Immunotherapy consisted of a single subcutaneous injection of CuMVtt coupled to Ara R, Ara h 1, or Ara h 2.
Results
The vaccines CuMVtt-Ara R, CuMVtt-Ara h 1, and CuMVtt-Ara h 2 protected peanut …
学术搜索中的文章
F Storni, A Zeltins, I Balke, MD Heath, MF Kramer… - Journal of Allergy and Clinical Immunology, 2020